TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25516196
Drug: Placebo 3×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3× daily via nasogastric tube for 21 days
Study: 22951068
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (mean dose 95.7mg, SD 48.9)
Study: 22951068
Drug: Higher methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher methadone dose
Study: 22951068
Drug: Urine drug
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine drug screening (UDS) positive for opiates, cocaine, and amphetamines
Study: 19697301
Drug: Caffeine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (administered in one double-blind group)
Study: 14698135
Drug: Paclitaxel (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (weekly or every 3 weeks)
Study: 14698135
Drug: Paclitaxel (weekly)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (weekly)
Study: 12405649
Drug: Prebiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic mixture (6 g/d of a 70% raftilose and 30% raftiline mixture)
Study: 12405649
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g of maltodextrin powder)
Study: 9680679
Drug: Low inhibitory
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low inhibitory control conditions (e.g., misleading pictorial cues or arrows)
Study: 8021037
Drug: 0.4% SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% SnF2 gel (n = 30) used twice daily for 18 months
Study: 2681637
Drug: Recombinant somatropin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant somatropin, 0.1 mg/kg three times a week
Study: 30270047
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen administered within 1 hour of induction
Study: 30270047
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (treatment group)
Study: 29066159
Drug: n‐3 long‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 long‐chain polyunsaturated fatty acids (LCPUFA) 4 g/d for three months
Study: 26287149
Drug: Carboxymethyl-glucan (CM-G)
Normalized name: sodium carboxymethyl beta-glucan (DS 0.65-0.85)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethyl-glucan (CM-G) administered orally for 60 days
Study: 21429334
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (n = 32)
Study: 21429334
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n = 32)
Study: 17407369
Drug: Lisdexamfetamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine (50 or 100 mg doses)
Study: 15065981
Drug: Sequential lineup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential lineup with absolute height encoding
Study: 11731354
Drug: Fluoxetine 10
Normalized name: fluoxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10 mg daily for 1 week, then increased to 20 mg daily
Study: 24622005
Drug: ASCEND-HF trial
Normalized name: Prascend
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCEND-HF trial patients (Nesiritide treatment)
Study: 24622005
Drug: Population-level cohorts
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population-level cohorts (not specified treatment)
Study: 16526312
Drug: Oral bicarbonate
Normalized name: sodium bicarbonate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bicarbonate therapy (1.2 mEq/kg of body weight daily)
Study: 1750016
Drug: Nasal sprays
Normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal sprays of recombinant alpha 2 interferon (3 x 10(6) IU) twice daily for five days
Study: 1750016
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for five days
Study: 30820429
Drug: Incise drape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incise drape (ID) used in treatment group
Study: 20848500
Drug: Open-label adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label adalimumab weekly therapy
Study: 20848500
Drug: Open-label adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label adalimumab EOW therapy
Study: 20848500
Drug: Blinded adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinded adalimumab EOW therapy
Study: 8660045
Drug: Ciprofloxacin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (70 mg/kg given over 7 d)
Study: 8660045
Drug: Ofloxacin (45‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (45‐50 mg/kg given over 3‐5 d)
Study: 6872416
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam 2 mg every 2 hr with supportive care (21 patients)
Study: 6872416
Drug: Sublingual placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual placebo every 2 hr with supportive care (20 patients)
Study: 6872416
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (21 drug group and 20 no-drug group)
Study: 30703096
Drug: Mass deworming
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass deworming treatment
Study: 24755106
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) for 6 weeks from a licensed renal social worker
Study: 22318468
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg daily for 6 weeks
Study: 22318468
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2,400 mg daily for 6 weeks
Study: 17448578
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral vaccine for enterotoxigenic E. coli (ETEC) diarrhoea, two doses with colonization factor antigens (CF) and cholera B subunit
Study: 12421104
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg/day as an adjunct to radiotherapy, radical prostatectomy or watchful waiting
Study: 12421104
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg/day monotherapy
Study: 9708750
Drug: Levonorgestrel (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (0.75 mg, repeated 12 h later)
Study: 9708750
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (ethinyloestradiol 100 microg plus levonorgestrel 0.5 mg, repeated 12 h later)
Study: 8567563
Drug: Graded epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded epinephrine infusion (0.02-0.12 micrograms.kg-1.min-1)
Study: 8567563
Drug: Control test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control test (no epinephrine infusion)
Study: 23865591
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (HBB) 20-100 mg/day
Study: 16696804
Drug: mesalazine 2400
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mesalazine 2400 mg/day
Study: 18565598
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment (ear drops and saline solution)
Study: 18565598
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with systemic antibiotics
Study: 10505732
Drug: Sucralfate enemas
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate enemas (20 g/100 ml)
Study: 10505732
Drug: Methylprednisolone enemas
Normalized name: methylprednisolone acetate Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone enemas (20 mg/100 ml)
Study: 6581065
Drug: Fenoterol powder
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol powder for inhalation
Study: 6581065
Drug: Fenoterol spray
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol spray
Study: 27681016
Drug: Interdental brushes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdental brushes used daily with a standard manual toothbrush twice daily
Study: 17507702
Drug: Continued fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued fluticasone (100 microg twice daily)
Study: 17507702
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 or 10 mg each night)
Study: 11552615
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (10 procedures)
Study: 11552615
Drug: Sonophoresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonophoresis treatment (diclofenac gel, 10 procedures)
Study: 7768254
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ramipril orally
Study: 7768254
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ramipril intravenously
Study: 7768254
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ramiprilat intravenously
Study: 2283645
Drug: Diltiazem (60-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-180 mg twice daily)
Study: 2283645
Drug: Captopril (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-75 mg twice daily)
Study: 31530665
Drug: continued GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: continued GLP-1 RA therapy
Study: 29978268
Drug: 940-nm diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 940-nm diode laser treatment after undisplaced flap surgery
Study: 29978268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgery without laser treatment)
Study: 26429974
Drug: Discontinue ACEi,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue ACEi, ARB or combination of both (experimental arm)
Study: 26429974
Drug: Continue ACEi,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue ACEi, ARB or combination of both (control arm)
Study: 14643168
Drug: Ambroxol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (75 mg twice daily)
Study: 14643168
Drug: Ambroxol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (75 mg twice daily) in patients with more severe symptoms
Study: 8492965
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate (7500 mg/m2)
Study: 8492965
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (750 mg/m2)
Study: 25908089
Drug: Stenting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting plus best medical treatment
Study: 23427864
Drug: metformin+pioglitazone combination
Normalized name: metformin / pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin+pioglitazone combination
Study: 19368145
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Aloe arborescens (10 ml thrice daily)
Study: 19368145
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Aloe arborescens
Study: 16442593
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 every 3-week cycle) and carboplatin (area under the curve of 5 every 3-week cycle)
Study: 16442593
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m2 every 3-week cycle)
Study: 11424018
Drug: Topical resiquimod
Normalized name: Resiquimod
DrugBank: Resiquimod (DB06530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical resiquimod gel 0.01% (twice or thrice weekly) or 0.05% (once or twice weekly)
Study: 8618466
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy of varying intensities (specific details not provided)
Study: 8618466
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment (specific details not provided)
Study: 1533542
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg kg‐1
Study: 1533542
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg kg‐1
Study: 1533542
Drug: 6 and
Normalized name: Plasma-Lyte 56 and 5% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 and 12 mg kg‐1
Study: 25156968
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (40 mg/d)
Study: 25156968
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil supplementation (2 g/d)
Study: 22192409
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPM and distraction
Study: 20338728
Drug: Ketoprofen administered
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen administered 60 min preoperatively
Study: 20338728
Drug: Ketoprofen administered
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen administered 60 min postoperatively
Study: 18843872
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (5 mg) 1-tablet three times daily for three months
Study: 18843872
Drug: Placebo 1-tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1-tablet three times daily for the first month
Study: 3894551
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine medication (one active medication patch)
Study: 30360970
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg orally once daily for 12 weeks
Study: 30360970
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily for 12 weeks
Study: 23360100
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU AVP (administered nasally)
Study: 23360100
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered nasally)
Study: 15305186
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 2000 mg m(‐2) day(‐1)
Study: 15305186
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1800 mg m(‐2) day(‐1)
Study: 15305186
Drug: Capecitabine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (various dose levels)
Study: 8400675
Drug: Indomethacin (IDM)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IDM) 50 mg every 8 hours for 4 days
Study: 8400675
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IDM or other non-steroidal anti-inflammatory drug)
Study: 29703528
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplements (fish oil and flaxseed oil)
Study: 26321018
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of arginine vasopressin 1A and 1B receptor agonist
Study: 18341378
Drug: Amifostine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (300 mg/m2 intravenously before 131I administration)
Study: 18341378
Drug: Dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 131I
Study: 12213943
Drug: Reviparin (1750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (1750 anti-Xa units given once daily)
Study: 7485128
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g intravenously after every dialysis session for 6 months)
Study: 6988106
Drug: Flunisolide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (200 micrograms total: 25 micrograms/actuation, 2 actuations into each nostril twice a day)
Study: 25880498
Drug: Short educational
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short educational program for primary care professionals including a decision support tool and monthly feedback report.
Study: 25880498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of educational interventions for patients and professionals.
Study: 21325473
Drug: High-soy diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soy diet (2 servings/day: 177 mL soy milk, 126 g tofu, or 23 g soy nuts) for 6 months
Study: 19919978
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination isosorbide-dinitrate/hydralazine
Study: 15090059
Drug: Concurrent tone
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent tone of constant intensity delivered dichotically at the contralateral ear (left)
Study: 2807359
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Metoprolol (0.36 to 0.65 mg/kg/day)
Study: 2807359
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Metoprolol (0.66 to 0.99 mg/kg/day)
Study: 2807359
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Metoprolol (1 to 1.81 mg/kg/day)
Study: 2807359
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with Goteberg Metoprolol trial and MIAMI trials (200 mg/day)
Study: 1103934
Drug: 2% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% miconazole in cream and powder base
Study: 31926893
Drug: Erbium glass,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium glass, 1540 nm laser treatment 24 hours before surgery
Study: 12855928
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d spironolactone (DIUR)
Study: 12855928
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and diuretic (EXDI)
Study: 11239617
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral mifepristone followed by 800 microg vaginal misoprostol at 24, 48, or 72 h
Study: 1355209
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy supplement (HE) providing 1950 kJ (465 kcal) during the last trimester of pregnancy
Study: 1355209
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy supplement (LE) providing 218 kJ (52 kcal) during the last trimester of pregnancy
Study: 1355209
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy supplement (HE)
Study: 6347428
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (975 mg/day)
Study: 6347428
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (225 mg/day)
Study: 30352778
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g olive oil)
Study: 19291926
Drug: Betamethasone injection
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone injection (Group A)
Study: 19291926
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) (Group B)
Study: 9802368
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide turbohaler (1600 micrograms)
Study: 15136063
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Probucol and Ticlopidine)
Study: 11214732
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (SO) 15 mL daily for 14 months
Study: 11214732
Drug: Cod-liver oil
Normalized name: Cod-liver oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod-liver oil (CLO) 15 mL daily for 14 months
Study: 3400902
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (Medrol tablets, Upjohn)
Study: 3400902
Drug: Topical vasoconstrictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vasoconstrictor (oxymetazoline spray)
Study: 26681272
Drug: TachoSil patch
Normalized name: fibrinogen / thrombin Medicated Patch [TachoSil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil patch